Institutional experience with nab-sirolimus in patients with malignancies harboring TSC1 or TSC2 mutations

Home Institutional experience with nab-sirolimus in patients with malignancies harboring TSC1 or TSC2 mutations

Institutional experience with nab-sirolimus in patients with malignancies harboring TSC1 or TSC2 mutations

/ Publications

Share the Post

About the Author

Related Posts

AADi Announces Licensing Agreement with Celgene for Nanotechnology-Based Drug Candidate
Pacific pride: Abraxis veteran grooms dormant Celgene drug for success
Aadi Bioscience Appoints Scott Giacobello as Chief Financial Officer
ABI-009 (nab-sirolimus) in Advanced Malignant Perivascular Epithelioid Cell Tumors (PEComa): Preliminary Efficacy, Safety, and Mutational Status from AMPECT, an Open-label Phase II Registration Trial
Read More
Bryan Ball
Aadi Bioscience Launches its Phase 2 Registration Trial for ABI-009PEComa
Aadi Bioscience to Announce First Quarter 2022 Financial Results on May 12, 2022
Phase II Trial of nab-sirolimus in Patients with Advanced Malignant Perivascular Epithelioid Cell Tumors (AMPECT): Long-Term Efficacy and Safety Update

Comments

Comments are closed.